Aquestive Therapeutics's Anaphylm could be the first FDA-approved, non-invasive, orally delivered epinephrine for anaphylaxis, with a PDUFA date set for January 2026. The FDA's decision not to convene ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Rating: BUY (Strategic Accumulation)Risk: Speculative/HighPrice Target: ~$6/share (53% upside)On January 9, 2026, Aquestive Therapeutics (AQST) disclosed receipt of a notification from the FDA stating ...
The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing ...
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive” or the "Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Aquestive Therapeutics (NASDAQ:AQST) presented its fourth quarter and full year 2025 earnings results on March 5, 2026, detailing the company’s response to a regulatory setback for its lead product ...
Aquestive’s Q4 2025 earnings missed expectations, with EPS at -$0.26 versus a forecast of -$0.13. Revenue increased by 10% year-over-year to $13 million, driven by manufacturing and supply growth. The ...
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful ...
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results